CTT Pharma Appoints David Paton as Senior Advisor

 

 

Tampa, Florida, United States – The Newswire – March 28, 2023 – CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) is pleased to announce David Paton has become a Senior Advisor for CTT Pharma effective April 1, 2023.

Mr. Paton previously worked for British American Tobacco (BAT) for 11 years in several Vice-President level innovation roles. Amongst these, David was Head of Product Development for Tobacco Heating Products, where he led the development through launch of glo in 2016. During his last four years at BAT, David served as Head of Discovery and Head of Open Innovation, while also managing numerous technology partnerships with start-up and scale-up companies. David also spent 10 years at Kimberly-Clark as a Senior Scientist and Technical Consultant, giving him more than two decades of experience in product development and R&D Leadership roles. David Paton stated, “I am thrilled to have been appointed as a Senior Advisor for CTT. I cannot wait to contribute my expertise and help drive the company towards success through their exciting product plans.”

Ryan Khouri, CEO of CTT Pharma, stated “David’s years of work at British American Tobacco and Kimberly-Clark in product development and R&D leadership roles will provide me with valuable insight into future development and partnerships for our patented technology. I’m excited that he has joined CTT Pharma and look forward to future opportunities.

CTT will continue to update shareholders as more news becomes available.

About CTT Pharma

CTT’s patented dissolvable strips enter the bloodstream once dissolved in the mouth, bypassing the lungs and digestive tract, allowing for better absorption, faster onset, as fast as an injection, and the ability to combine actives. This technology can be used for many industries including but not limited to Pharmaceuticals, Nicotine, and Vitamins. Furthermore, CTT has the ability to create smoke-free products with less milligrams of a desired drug needed on a strip than traditional oral delivery methods because of higher bioavailability and absorption.

CTT Pharma – 813-606-0060

Rkhouri@cttpharmaceuticals.com

CTT Pharma Updates On Worldwide Patent Portfolio

 

 

Tampa, Florida, United States – The Newswire – December 19, 2022 – CTT Pharmaceutical Holdings, Inc.(OTC:CTTH) has received patent approval in Israel for our dissolvable strip technology. This latest patent approval gives CTT up to 48 granted patents, including three patents in the United States, three in Canada, Europe, Australia, South Africa, Mexico, and Israel. Europe covers up to 38 countries, which includes The United Kingdom, Germany, France, Switzerland, and Italy to name a few.
CTT also has 9 patents pending, which includes four patents pending in the United States, three in Canada, Brazil, and Chile. In 2021 CTT secured pending patents in the US and Canada to cover Psychedelics using our technology and in 2022 CTT strengthened our patents by filing a continuation from an existing granted US Patent to broaden protection for Nicotine, Vitamins, and Caffeine. The nicotine patents were a priority for CTT as they offer a smoke-free alternative to smoking or vaping and would be one of the few oral nicotine products on the market, that dissolve in your mouth in seconds. CTT also recently filed two new patents in the US and two in Canada to further strengthen existing patents offering protection for Pharmaceuticals, Nicotine, Vitamins, and other medicinal actives.

Ryan Khouri, CEO of CTT Pharma, stated that we have made a tremendous amount of progress with our patents in a short period of time. Furthermore, these patents give CTT the ability to align with partners that have a global reach.

About CTT Pharma

Our patented technology offers protection using many different APIs on dissolvable strips and in other oral deliverables. CTT successfully received Health Canada approval for our dissolvable strips and sold out in weeks with no advertising. CTT’s dissolvable strips enter the bloodstream once dissolved in the mouth, bypassing the lungs and digestive tract, allowing for better absorption, faster onset, as fast as an injection, and the ability to combine products.

CTT will continue to update shareholders as more news becomes available .

CTT Pharma – 813-606-0060

Rkhouri@cttpharmaceuticals.com

Safer, Faster, Better

CTT Pharmaceutical’s patented technology allows us to put THC, CBD, Nicotine, Pharmaceutical, Neutriceuticals and Caffeine on dissolvable strips.

Our strips offer the following:

  • Enters bloodstream quickly
  • Bypasses lungs and digestive tract(Including liver)
  • Better bioavailability(which means less product needed)
  • Fast Onset(Strips work as quick as an injection)
  • Any Flavor
  • Any color strip
  • Smoke-free
  • Dosage Control

CTT Pharma recieved Health Canada Approval for our dissolvable strips and successfully brought to market and sold-out these strips in less than 60 days. We currently have several patents in both the USA and Canada and have patents pending in over 55 countries.

CTT is currently looking for and engaging companies in each industry our technology can be used. We believe our Dissolvable Strips are the next evolution in offering a safer, faster, better option. Our many different product lines will create new industries with little to no competition and our patents will help to protect the market that is being created.

  • Loading stock data...